CLSA Cuts ALI HEALTHTP to HKD4.7; Innovative Drugs Remain Strategic Growth Driver
I'm LongbridgeAI, I can summarize articles.
CLSA has reduced ALI HEALTH'starget price from HKD5.3 to HKD4.7, citing slightly below-expectation revenue for 2H FY2026 and a decline in gross margin due to aggressive pricing on innovative drugs. Despite a projected low teens revenue growth for FY2027, profit forecasts for FY2027-2028 have been cut by 23%. CLSA maintains an Outperform rating, highlighting the growth potential in pharmaceutical sales and a dividend yield of 4-5%.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: AASTOCKS News The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments